# Supplementary Materials

## Supplementary Table S1. Treatments prescribed to ≥2% of patients with MCL by treatment line

| First-line treatment | Second-line treatment | Third-line treatment |
|----------------------|-----------------------|----------------------|
| N = 802              | N = 408               | N = 213              |
| BR 223 (27.8%)       | BR 77 (18.9%)         | BR 29 (13.6%)        |
| R-CHOP 125 (15.6%)   | Ibrutinib 41 (10.0%)  | Ibrutinib 26 (12.2%) |
| R-THP-COP 52 (6.5%)  | B 26 (6.4%)           | R 12 (5.6%)          |
| VR-CAP 47 (5.9%)     | Etoposide (VP16) 14 (3.4%) | B 8 (3.8%) |
| R 41 (5.1%)          | Ibritumomab tiuxetan 14 (3.4%) | R-ICE 5 (2.3%) |
| R-Hyper-CVAD/MA 34 (4.2%) | R-CHOP 12 (2.9%)    |                    |
| Ibrutinib 20 (2.5%)  | MEAM 11 (2.7%)        |                    |
| B 19 (2.4%)          | R-Hyper-CVAD/MA 10 (2.5%) |                |
|                     | VR-CAP 10 (2.5%)      |                    |
|                     | CHASER 9 (2.2%)       |                    |
|                     | MA 8 (2.0%)           |                    |

B, bendamustine; R, rituximab; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisolone; VR-CAP, bortezomib/rituximab/cyclophosphamide/doxorubicin/prednisolone; THP, tetrahydropyranyl-adriamycin; COP, cyclophosphamide/vincristine/prednisolone; hyper-CVAD, hyperfractionated cyclophosphamide/vincristine/doxorubicin/dexamethasone; MEAM, ranimustine/etoposide/cytarabine/melphalan; CHASER, cyclophosphamide/cytarabine/dexamethasone/etoposide/rituximab; MA, methotrexate/cytarabine; ICE, ifosfamide/carboplatin/etoposide
Supplementary Fig. S1. Kaplan–Meier plots of TIT (a), TFST (b), and TSST (c) in patients who did not undergo stem cell transplantation during the follow-up period. TIT was calculated as the time from the index date (date of first MCL diagnosis) to the first prescribed antineoplastic treatment. TFST and TSST were calculated as the time from the first prescription to the prescription of second-line (TFST) or third-line (TSST) treatments. TIT, time to initial (i.e., first-line) treatment; TFST, time to first-subsequent (i.e., second-line) treatment; TSST, time to second-subsequent (i.e., third-line) treatment.
Supplementary Fig. S2. Kaplan–Meier plots of TIT (a), TFST (b), and TSST (c) in patients who did not undergo stem cell transplantation during the follow-up period stratified by age at the index date (≤65 or >65 years). TIT was calculated as the time from the index date (date of first MCL diagnosis) to the first prescribed antineoplastic treatment. TFST and TSST were calculated as the time from the first prescription to the prescription of second-line (TFST) or third-line (TSST) treatments. TIT, time to initial (i.e., first-line) treatment; TFST, time to first-subsequent (i.e., second-line) treatment; TSST, time to second-subsequent (i.e., third-line) treatment.